[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer---ovarian\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer---ovarian":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,56,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100615261","survivors-uniting-for-remote-guided-exercise-100615261",false,"NCT07290309","Survivors Uniting for Remote Guided Exercise","Efficacy of a Group-based Videoconference Intervention to Increase Physical Activity in Cancer Survivors","SURGE","Inclusion Criteria:\n\n* Able to speak\u002Fread English,\n* Diagnosed with any type of cancer within the last 5 years\n* Completed primary or adjuvant treatment (i.e., chemotherapy, radiation therapy, surgery) with no planned treatment within the next nine months. This does not include long-term or chronic therapies such as anti-hormone or targeted therapies (e.g., aromatase inhibitor, androgen deprivation therapy, immunotherapies)\n\nExclusion Criteria:\n\n* Existing participation in ≥150 minutes per week of at least moderate intensity aerobic exercise\n* Known contraindications for non-medically supervised moderate or greater intensity exercise (e.g., uncontrolled hypertension, inability to walk without an assistive device)\n* Current or planned participation in another structured program or intervention intended to encourage participation in exercise or physical activity.","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this research study is to look at how live, online group exercise compares to recorded videos for helping increase physical activity levels, improve physical fitness and quality of life, and reduce loneliness among those living with and beyond cancer. The following aims have been established for this study:\n\n* Aim 1: Examine the effect of a group-based videoconference physical activity (PA) intervention on moderate to vigorous physical activity \\[MVPA\\] (i.e., aerobic and resistance exercise).\n* Aim 2: Examine the effect of the intervention on additional health-related outcomes including physical fitness (i.e., aerobic endurance, muscular strength), and quality of life at both timepoints.\n* Aim 3: Explore potential mediators and moderators of intervention effects. We will examine mediators (e.g., self-efficacy, outcome expectations, group cohesion) and moderators (e.g., age, cancer stage, neighborhood walkability) of the intervention on MVPA.\n* Exploratory Aim: Determine whether a group-based videoconference PA intervention reduces loneliness among cancer survivors.\n\nResearchers will randomize participants into one of two guided exercise groups that are 12-weeks long in duration. Participants will be asked to complete online fitness assessments and surveys as well as wear a physical activity monitor device and watch a few times throughout the study. The whole study is 9-months long in duration with a 6-month free-living period where no study activities will take place.",[27,28,29,30,31,32,33],"Cancer","Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)","Physical Activity","Physical Activity Behavior","Cancer (With or Without Metastasis)","Cancer - Chronic Lymphocytic Leukemia","Cancer - Ovarian",[35,36,37,38,39,40,41,42],"Exercise oncology","Physical activity for cancer survivors","Group based exercise","Virtual exercise","physical activity","exercise","remote study","Cancer survivors","RECRUITING","2026-03-27",{"date":46,"type":47},"2026-03-31","ACTUAL",{"date":49,"type":47},"2026-02-06",{"date":51,"type":21},"2030-03-01",{"name":53,"class":54},"Colorado State University","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":64,"targetDuration":66,"studyType":67,"phases":4,"briefSummary":68,"conditions":69,"keywords":74,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100626286","wellspan-thrive-cancer-qol-study-100626286","NCT07433660","WellSpan-THRIVE Cancer QOL Study","WellSpan Study of Tracking Health and Resilience to Improve the Vitality of Individuals Experiencing Cancer [WellSpan-THRIVE]","THRIVE","Inclusion Criteria:\n\n* Age 18 years and above\n* Primary cancer diagnosis (newly diagnosed within the past 6 months)\n* Able to sign informed consent.\n\nExclusion Criteria:\n\n* Patients with age\\\u003C18 years,\n* Patients with primary non-melanoma skin, neurological malignancies (Brain or brain metastases), and primary hematological malignancies.\n* Patients with severe cognitive impairment, unable to sign informed consent or unable to complete quality of life questionnaire.\n* Patients with life expectancy of \\\u003C90 days, in the opinion of treating investigator.",{"count":65,"type":21},1000,"24 Months","OBSERVATIONAL","Cancer affects millions of people worldwide and can significantly impact not only survival, but also day-to-day quality of life. Treatments such as surgery, chemotherapy, and radiation can cause side effects like fatigue, pain, and neuropathy, which may affect physical function, emotional well-being, and social relationships. While many studies have examined factors that influence quality of life; such as age, type and stage of cancer, and treatment-related symptoms; there is still a need for tools that more fully reflect patients' lived experiences.\n\nThis study aims to develop and implement a patient-centered quality of life (QOL) survey designed specifically for individuals with cancer. By directly involving patients in sharing what matters most to them, the survey seeks to provide a more complete and accurate understanding of how cancer and its treatment affect daily life. The results will help patients, families, and healthcare providers better identify needs, guide supportive care, and improve overall well-being throughout the cancer journey.",[70,71,31,33,72,73],"Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment\u002FCare Regimen; i.e. Curative, Life-extending, or Palliative","Cancer (Solid Tumors)","Cancer Abdomen","Cancer (Advanced Stage)",[27,75,76,77,78],"Quality of Life","QOL","Registry","Patient","2026-02-26",{"date":81,"type":47},"2026-03-02",{"date":83,"type":21},"2026-02",{"date":85,"type":21},"2031-12",{"name":87,"class":54},"WellSpan Health",5,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":97,"minAge":18,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":100,"conditions":101,"keywords":102,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":4},"100624240","a-study-to-evaluate-folate-receptor-alpha-fr-expression-in-adult-participants-with-ovarian-fallopian-tube-and-primary-peritoneal-cancer-in-italy-100624240","NCT07407062","A Study to Evaluate Folate Receptor Alpha (FRα) Expression in Adult Participants With Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in Italy","Folate Receptor Alpha Expression in Relapsed Ovarian, Fallopian Tube and Primary Peritoneal Cancer: a Realworld prEvalence Study in Italy","FORCE","Inclusion Criteria:\n\n* Relapsed ovarian, fallopian tube and primary peritoneal cancer\n* Histologically high-grade serous carcinoma\n* Presence of archived surgical tissue samples from participants with epithelial ovarian cancer at diagnosis and at 1st recurrence in the same participants\n* Available samples collected from January 1st, 2016 to study start date (defined as study site initiation visit date) that are considered adequate for the Ventana folate receptor alpha (FOLR1) RxDx assay by the site pathologist\n\nExclusion Criteria:\n\n* Histological ambiguous diagnosis upon review\n* Diagnosis based on cytology and without any biopsy or surgical specimen\n* Other histotypes than high grade serous ovarian cancer, fallopian tube cancer and primary peritoneal cancer\n* Archival or recurrent sample for the same participant not available","FEMALE",{"count":99,"type":21},200,"The purpose of this study is to evaluate the prevalence of folate receptor alpha (FRα)-positive status (≥75% viable tumor cells with moderate (2+) and\u002For strong (3+) membrane staining) in participants with high-grade serous ovarian, fallopian tube, and primary peritoneal cancer, stratified by time of sampling (initial diagnosis versus relapse), adhering to Ventana folate receptor alpha (FOLR1) RxDx (prescription diagnosis) assay Interpretation Guidance.",[33],[33],"NOT_YET_RECRUITING",{"date":105,"type":47},"2026-02-12",{"date":107,"type":21},"2026-02-28",{"date":109,"type":21},"2026-07",{"name":111,"class":112},"AbbVie","INDUSTRY"]